8F0803, 08049FResponsible DepartmentDepartment of Clinical Research in Tumor ImmunologyResearch PartnerShionogi & Co., Ltd.Responsible DepartmentDepartment of Advanced Clinical and Translational ImmunologyResearch PartnerChugai Pharmaceutical Co., Ltd.23230903Emerging interest in new cancer immunotherapy through the regulation of immunosuppressive mechanisms has attracted worldwide attention because of the remarkable clinical effects of immune checkpoint inhibitors. With the full support of Professor Sakaguchi (IFReC), who discovered regulatory T cells (Tregs), our laboratory explores mechanisms to regulate various immunosuppressive cells, especially Tregs, to chase up new drug seeds for clinical application of cancer immunotherapy in collaboration with Shionogi & Co., Ltd. To conduct clinically oriented research, especially detailed analysis in tumor micro-environment, we have established close cooperation with the departments of gastroenterological surgery, gynecology, urology, dermatology, breast surgery, head and neck surgery, respiratory surgery, and respiratory medicine. Through this broad collaboration, we have newly identified and patented “CCR8”, uniquely expressed on tumor-infiltrating Tregs. Furthermore, we have produced an antibody drug targeting CCR8, and a clinical trial has been initiated in 2022.Immunology research has brought many new discoveries and findings as a driving force in medicine and life sciences. The achievements have been applied to the development of biologics for rheumatoid arthritis and allergic diseases, as well as to cancer immunotherapy with anti-immune checkpoint antibodies, and have a great impact on clinical practice today. However, there are still many intractable immune diseases and cancers for which there is no cure, and clinical applications based on research progress and new findings are required.With these backgrounds, the project promotes integrated analysis and verify human-derived samples using advanced immunological techniques based on the research achievements of immunology at Osaka University. From the results obtained, we aim to develop new therapeutic methods by cooperation with Chugai Pharmaceutical Co., Ltd. drug discovery technology.A-4A-20KUMANOGOH Atsushi ProfessorDepartment of Respiratory Medicine and Clinical ImmunologyWADA HisashiSpecially Appointed ProfessorDepartment of Clinical Research in Tumor ImmunologyNARAZAKI MasashiSpecially Appointed ProfessorDepartment of Advanced Clinical and Translational ImmunologyClinical research for regulatory factors in tumor immunologyDevelopment of innovative therapies for intractable immune disease and cancer by targeting neuro, immune and metabolic regulatory factors
元のページ ../index.html#24